Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

Posted on by

Lancet Infectious Diseases
Apr 2020 Volume 20 Number 4 p383-510, e50-e78
http://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial
David K Clarke, ey al